Regent Peak Wealth Advisors’s Boston Scientific BSX Stock Holding History

Regent Peak Wealth Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,260	Closed	-$215K	–	201
2025 Q4	$215K	Buy	+2,260	New	+$222K	0.04%	171
2021 Q1	–	Sell	-567	Closed	-$20K	–	262
2020 Q4	$20K	Buy	+567	New	+$20.4K	0.01%	449

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Regent Peak Wealth Advisors's BSX Position: Q1 2026 in Review

Regent Peak Wealth Advisors sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 2,260 shares — an estimated $215K sold.

Regent Peak Wealth Advisors first reported a position in BSX in Q4 2020 and held it in 2 quarters. The position peaked at $215K in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Regent Peak Wealth Advisors reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Regent Peak Wealth Advisors sold 2,260 Boston Scientific shares in Q1 2026, an estimated $215K.
Regent Peak Wealth Advisors first reported a position in Boston Scientific in Q4 2020 and held it in 2 quarters.
Regent Peak Wealth Advisors's Boston Scientific position peaked at $215K in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Regent Peak Wealth Advisors's 13F filing for Q1 2026, filed 14 Apr 2026.